ASLAN Pharmaceuticals Faces Nasdaq Delisting

Aslan Pharmaceuticals (ASLN) has released an update.

ASLAN Pharmaceuticals, a biopharmaceutical company focused on immunology, has been notified by Nasdaq of its securities delisting due to non-compliance with listing requirements. The company, which recently underwent a ratio change of its shares to boost share price, has decided not to appeal the delisting determination. Despite a temporary boost in share price above the required threshold, ASLAN did not meet Nasdaq’s continued listing standards in bid price and stockholders’ equity.

For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.